Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | JNJ-87801493 |
Trade Name | |
Synonyms | JNJ 87801493|JNJ87801493 |
Drug Descriptions |
JNJ-87801493 is a bispecific antibody targeting CD20 on B-cells and CD28 on T-cells, which potentially enhances T-cell activation and inhibits tumor growth (Blood (2024) 144 (Supplement 1): 1408). |
DrugClasses | CD20 Antibody 25 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
JNJ-75348780 + JNJ-87801493 | JNJ-75348780 JNJ-87801493 | 0 | 1 |
JNJ-80948543 + JNJ-87801493 | JNJ-80948543 JNJ-87801493 | 0 | 1 |
JNJ-87801493 | JNJ-87801493 | 0 | 0 |